Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cell. It is available as oral delayed-release tablets/suspension and an intravenous (IV) formulation.
## Primary Indications
* Treatment of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Short-term treatment of GERD-associated symptoms.
## Adult Dosing
* **Erosive Esophagitis:** 40 mg PO or IV daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg PO daily.
* **Hypersecretory Conditions:** Starting dose 40 mg PO twice daily. Doses up to 240 mg daily have been used; adjust based on clinical response and acid output.
* **Stress Ulcer Prophylaxis (Off-label/Institutional Protocol):** 40 mg IV daily.
## Pediatric Dosing
* **GERD (5 years and older):**
* 15 kg to <40 kg: 20 mg PO daily.
* ≥ 40 kg: 40 mg PO daily.
* **Erosive Esophagitis (5 years and older):** Same dosing weight-based regimen as GERD.
* *Note: Safety and efficacy for IV use in pediatrics are not well-established.*
## Dose Adjustments
* **Hepatic Impairment:** No initial dosage adjustment required, but monitor liver enzymes if liver disease is severe; consider reducing frequency in chronic liver failure.
* **Renal Impairment:** No dosage adjustment necessary.
## Contraindications
* Known hypersensitivity to pantoprazole or any substituted benzimidazole (e.g., omeprazole, lansoprazole).
* Concurrent use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, and increased risk of bone fractures (hip, wrist, spine) with high-dose/long-term therapy.
## Key Drug Interactions
* **pH-Dependent Drugs:** May decrease absorption of drugs requiring acidic environments (e.g., atazanavir, ketoconazole, iron salts, mycophenolate mofetil).
* **Methotrexate:** PPIs may increase methotrexate levels; use caution, especially in high-dose therapy.
* **Warfarin:** Monitor INR frequently as PPIs may alter metabolism/clearance.
## Monitoring
* Monitor for signs of hypomagnesemia (fatigue, tetany, seizures) during long-term therapy (>1 year).
* Monitor periodic vitamin B12 levels if on long-term therapy.
* Monitor for symptoms of CDAD (persistent watery diarrhea).
## Clinical Pearls
* **Administration:** Administer PO doses 30–60 minutes before a meal.
* **IV Bolus:** When given IV, administer as a 15-minute infusion or a 2-minute bolus (per institutional protocol).
* **Discontinuation:** Tapering is recommended for long-term users to avoid rebound hypersecretion.
* **Clinical Uncertainty:** Always verify site-specific protocols for stress ulcer prophylaxis (SUP), as many institutions are attempting to de-escalate overuse of PPIs in the ICU.
***
*Disclaimer: This information is for educational purposes only. Always consult the most current prescribing information, institutional guidelines, and clinical pharmacology databases (e.g., Lexicomp or Micromedex) before prescribing or administering medication.*
